Gyre Therapeutics Inc.
GYRE | NASDAQ
$4.55
-$1.86 (-29.02%)
At close: Oct 30, 2026, 4:00 PM ET
$4.79
+$0.24 (+5.27%)
Pre-market:
Nov 2, 2026, 8:02 AM ET
Market Data
Market Cap $482.98M
Enterprise Value $411.61M
Beta 4.74
Average Volume 119.37K
Shares Outstanding (Diluted) 100.64M
Shares Change YoY 12.82%
Institutional Ownership 9.69%
Exchange NASDAQ
ISIN US4037831033
Price Performance
Price Change 1M -37.9%
Price Change 3M -20.9%
Price Change 6M -41.7%
Price Change YTD -35.5%
Price Change 1Y -41.3%
Price Change 3Y -32.4%
Price Change 5Y -90.8%
1M CAGR (ann.) -39.6%
1Y CAGR (ann.) -39.5%
5Y CAGR (ann.) -37.6%
All-Time CAGR -29.5%
Valuation
PE Ratio -22.75
Forward PE 87.00
PEG Ratio 0.25
Forward PEG 0.07
PS Ratio 4.05
Forward PS 3.50
PB Ratio 3.71
P/FCF Ratio -28.77
P/Adj. FCF Ratio -19.63
P/OCF Ratio -32.50
EV/Sales 3.45
EV/EBIT -25.55
EV/EBITDA -29.35
EV/FCF -24.52
Earnings Yield -4.4%
FCF Yield -3.5%
Adj. FCF Yield -5.1%
Financial Health
Net Cash $74.8M
Total Debt $3.42M
Cash & Short-Term Investments $74.8M
Total Assets $199.26M
Current Ratio 4.26
Quick Ratio 3.86
Debt / Equity Ratio 0.03
Debt / EBITDA -0.24
Debt / FCF -0.20
OCF / Debt -4.24
Interest Coverage 0.00
Altman Z-Score 8.37
Piotroski F-Score 1
Margins & Profitability
Gross Profit Margin 94.3%
Operating Profit Margin -14.0%
EBITDA Margin -10.6%
Net Profit Margin -14.5%
FCF Margin -14.1%
Adj. FCF Margin -20.6%
SBC / Revenue 6.5%
SBC Impact (per share) -46.6%
Returns
Return on Assets -8.7%
Return on Equity -15.8%
Return on Invested Capital -9.7%
Return on Capital Employed -9.8%
Return on Tangible Assets -8.9%
Historical Growth (CAGR)
Revenue CAGR 3Y 2.2%
Revenue CAGR 5Y 84.9%
Revenue CAGR 10Y 75.3%
EPS CAGR 3Y 106.6%
EPS CAGR 5Y 31.0%
EPS CAGR 10Y 37.1%
FCF CAGR 3Y -175.8%
FCF CAGR 5Y 43.8%
FCF CAGR 10Y 18.2%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y 88.3%
Revenue Growth Next 3Y 30.4%
Earnings Date Nov 6, 2026
EPS Estimate (next Q) -$0.15
EPS Growth Est (next Q) -350.0%
Revenue Est (next Q) $28.4M
Revenue Growth Est (next Q) -7.1%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $17.00
Price Target Upside 273.6%
Cash Flow
Operating Cash Flow $-14.5M
Free Cash Flow $-16.79M
Adj. Free Cash Flow $-24.61M
FCF Per Share -$0.17
OCF Per Share -$0.14
OCF/S Ratio -12.1%
Income Statement
Revenue $119.38M
Gross Profit $112.58M
Operating Income $-16.67M
EBITDA $-14.03M
Net Income $-17.33M
EPS (Diluted) -$0.20
Revenue / Employee $191.01K
Profit / Employee $-27.73K
Employees 625
Add to Watchlist
Select watchlists to add or remove GYRE